Fairmont Chateau Whistler Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2018
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
HIV and Co-Infections: Pathogenesis, Inflammation and Persistence (X8)
Organizer(s) Irini Sereti, Nicolas Chomont and Michaela Müller-Trutwin
April 15—19, 2018
Fairmont Chateau Whistler • Whistler, BC Canada
Discounted Abstract Deadline: Dec 13, 2017
Abstract Deadline: Jan 11, 2018
Scholarship Deadline: Dec 13, 2017
Discounted Registration Deadline: Feb 15, 2018
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
Joint Meeting:
Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
Summary of Meeting:
Better understanding of HIV pathogenesis is the cornerstone for advances in HIV prevention and vaccine design, long-term therapies and strategies for remission or eradication. Despite remarkable progress in the care of HIV-infected individuals and successful conversion of HIV into a chronic disease, gaps in knowledge regarding the mechanisms of evasion of immune responses, establishment of latency and persistence, pathways involved in chronic inflammation and the potential role of co-infections persist and hamper the design of targeted interventions. This meeting aims to: 1) Deepen understanding the mechanisms of establishment and maintenance of HIV reservoirs including viral evolution on ART, epigenetic regulations and metabolic states; 2) Provide updates on innovative strategies for HIV remission and control; 3) Determine the role of TB and other co-infections in inflammation and establishment of HIV viral reservoirs; and 4) Explore the pathways that induce chronic inflammation and the molecular interplays between inflammation and viral reservoirs in chronic HIV infection. The conference is novel because it is being paired with Keystone Symposia’s conference on “Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact.” Of the estimated 34 million people living with HIV in the world today, more than a third are also infected with Mycobacterium tuberculosis. Important questions related to HIV pathogenesis including pathways of inflammation and establishment of reservoirs may be greatly influenced by TB and other co-infections. Inflammation and viral persistence are likely fueled by each other, which provides a rationale for addressing these two topics in the same conference. In addition, the meeting’s joint pairing with one dedicated to TB should facilitate interdisciplinary interactions and highlight the importance of TB in HIV pathogenesis and vice versa.
View Scholarships/Awards
Better understanding of HIV pathogenesis is the cornerstone for advances in HIV prevention and vaccine design, long-term therapies and strategies for remission or eradication. Despite remarkable progress in the care of HIV-infected individuals and successful conversion of HIV into a chronic disease, gaps in knowledge regarding the mechanisms of evasion of immune responses, establishment of latency and persistence, pathways involved in chronic inflammation and the potential role of co-infections persist and hamper the design of targeted interventions. This meeting aims to: 1) Deepen understanding the mechanisms of establishment and maintenance of HIV reservoirs including viral evolution on ART, epigenetic regulations and metabolic states; 2) Provide updates on innovative strategies for HIV remission and control; 3) Determine the role of TB and other co-infections in inflammation and establishment of HIV viral reservoirs; and 4) Explore the pathways that induce chronic inflammation and the molecular interplays between inflammation and viral reservoirs in chronic HIV infection. The conference is novel because it is being paired with Keystone Symposia’s conference on “Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact.” Of the estimated 34 million people living with HIV in the world today, more than a third are also infected with Mycobacterium tuberculosis. Important questions related to HIV pathogenesis including pathways of inflammation and establishment of reservoirs may be greatly influenced by TB and other co-infections. Inflammation and viral persistence are likely fueled by each other, which provides a rationale for addressing these two topics in the same conference. In addition, the meeting’s joint pairing with one dedicated to TB should facilitate interdisciplinary interactions and highlight the importance of TB in HIV pathogenesis and vice versa.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, April 15 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, April 19 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, April 20 in order to fully experience the meeting.
SUNDAY, APRIL 15
MONDAY, APRIL 16
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
TUESDAY, APRIL 17
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
WEDNESDAY, APRIL 18
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
THURSDAY, APRIL 19
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
FRIDAY, APRIL 20
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, April 15 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, April 19 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, April 20 in order to fully experience the meeting.
SUNDAY, APRIL 15
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:30
Welcome and Keynote Session (Joint)
*
Irini Sereti,
NIAID, National Institutes of Health, USA
*
Graeme Meintjes,
University of Cape Town, South Africa
Bruce D. Walker,
Ragon Institute of MGH, MIT and Harvard, USA
New Insights into HIV Pathogenesis: Implications for Immunotherapeutic Strategies
New Insights into HIV Pathogenesis: Implications for Immunotherapeutic Strategies
Gavin J. Churchyard,
Aurum Institute NPC, South Africa
Translating TB Science to Impact the Epidemic
Translating TB Science to Impact the Epidemic
Coffee Break
09:50—12:00
Off to a Strong Start: Lessons from Acute HIV Infection
*
Nicolas Chomont,
Université de Montréal, Canada
*
Ann Duerr,
Fred Hutchinson Cancer Research Center, USA
Thumbi Ndung'u,
University of KwaZulu-Natal, South Africa
Evidence of Transmission-Virulence Evolutionary Trade-Offs in the Spread of HIV-1 Subtypes
Evidence of Transmission-Virulence Evolutionary Trade-Offs in the Spread of HIV-1 Subtypes
Julie Mitchell,
Vaccine and Gene Therapy Institute, OHSU, USA
T Cell Responses in Acutely Infected Young Men in Thailand
T Cell Responses in Acutely Infected Young Men in Thailand
Elina El-Badry,
Emory University, USA
Short Talk: Zambian Women Exhibit an Exacerbated Inflammatory Response to Early HIV Infection Compared to Men
Short Talk: Zambian Women Exhibit an Exacerbated Inflammatory Response to Early HIV Infection Compared to Men
Heeva Baharlou,
Westmead Institute for Medical Research, Australia
Short Talk: HIV and the Colorectal Mucosa – Investigating the Early Interactions of HIV with Mucosal Target Cells in situ
Short Talk: HIV and the Colorectal Mucosa – Investigating the Early Interactions of HIV with Mucosal Target Cells in situ
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
09:50—12:15
Prospects for Epidemic Control and the Scientific Insights Required
*
Eric J. Rubin,
Harvard T.H. Chan School of Public Health, USA
*
Henry Charles Mwandumba,
Liverpool School of Tropical Medicine, UK
Mark Hatherill,
University of Cape Town, South Africa
Translating Transcriptomic Insights into Clinical Tools
Translating Transcriptomic Insights into Clinical Tools
Carole D. Mitnick,
Harvard Medical School, USA
(Re)Moving the Needle in Treatment for Rifampin-Resistant TB: The endTB Trial
(Re)Moving the Needle in Treatment for Rifampin-Resistant TB: The endTB Trial
Michael Gordon Whitfield,
Stellenbosch University, South Africa
Short Talk: The Potential of Rifabutin for the Treatment of Rifampicin-Resistant Tuberculosis
Short Talk: The Potential of Rifabutin for the Treatment of Rifampicin-Resistant Tuberculosis
Francesca Tomasi,
Harvard T. H. Chan School of Public Health, USA
Short Talk: Small Molecule Inhibitors of Amino Acid Metabolism in Mycobacterium tuberculosis: A Model with Acivicin
Short Talk: Small Molecule Inhibitors of Amino Acid Metabolism in Mycobacterium tuberculosis: A Model with Acivicin
Meera Gurumurthy,
International Union Against Tuberculosis and Lung Disease, Singapore
Short Talk: Randomised Controlled trial of Pascolizumab (Anti-IL-4 Monoclonal Antibody) as an Adjunct to Standard TB Treatment
Short Talk: Randomised Controlled trial of Pascolizumab (Anti-IL-4 Monoclonal Antibody) as an Adjunct to Standard TB Treatment
14:30—16:30
Workshop 1: Role of Metabolism and Inflammation in SIV/HIV Pathogenesis and Reservoirs
*
Asier Sáez-Cirión,
Institut Pasteur, France
*
Michael A. Eller,
US Military HIV Research Program, USA
Cristian Apetrei,
University of Pittsburgh, USA
High Fat Diet Exacerbates SIV Pathogenesis in SIVsab Infection Models
High Fat Diet Exacerbates SIV Pathogenesis in SIVsab Infection Models
Mohamed Abdel-Mohsen,
Wistar Institute, USA
Plasma and Immunoglobulin G Galactosylation Associate with HIV Persistence During Antiretroviral Therapy
Plasma and Immunoglobulin G Galactosylation Associate with HIV Persistence During Antiretroviral Therapy
Livia Ramos Goes,
Instituto Nacional de Cancer, Brazil
MAdCAM Costimulation in Presence of Retinoic Acid Promotes Viral Replication in Recently Activated Naïve CD4+ T Cells
MAdCAM Costimulation in Presence of Retinoic Acid Promotes Viral Replication in Recently Activated Naïve CD4+ T Cells
Virginie W. Gautier,
University College Dublin, Ireland
Targeting HIV Latency with Metabolic Cues
Targeting HIV Latency with Metabolic Cues
Sergei Nekhai,
Howard University, USA
Upregulated Iron Metabolism Induces Intrinsic HIV-1 Restriction in Sickle Cell Disease
Upregulated Iron Metabolism Induces Intrinsic HIV-1 Restriction in Sickle Cell Disease
Sandra Milena Gonzalez Diaz,
Universidad de Antioquia, Colombia
Active and Inactive Forms of Vitamin D Reduce the HIV-1 Infection of CD4+ T Cells in Vitro and Modulate their Activation Level
Active and Inactive Forms of Vitamin D Reduce the HIV-1 Infection of CD4+ T Cells in Vitro and Modulate their Activation Level
Emily Bowman,
Ohio State University, USA
Altered Macrophage Phenotype in HIV Infection May Contribute to Vascular Inflammation
Altered Macrophage Phenotype in HIV Infection May Contribute to Vascular Inflammation
Robert Blomgran,
Linköping University, Sweden
HIV Interferes with The DC-T Cell Axis of Macrophage Activation by Shifting Mycobacterium tuberculosis-Specific CD4 T Cells into a Dysfunctional Tolerized Phenotype
HIV Interferes with The DC-T Cell Axis of Macrophage Activation by Shifting Mycobacterium tuberculosis-Specific CD4 T Cells into a Dysfunctional Tolerized Phenotype
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
14:30—16:30
Workshop 1: TB Vaccines
*
Cesar A. Boggiano,
NIAID, National Institutes of Health, USA
*
Willem A. Hanekom,
Bill & Melinda Gates Foundation, USA
State of the TB Vaccine Field
State of the TB Vaccine Field
Karen Lacourciere,
NIAID, National Institutes of Health, USA
Funding Opportunities in TB Vaccine Research
Funding Opportunities in TB Vaccine Research
Lakshmi Ramachandra,
NIAID, National Institutes of Health, USA
Funding Opportunities in TB Vaccine Research
Funding Opportunities in TB Vaccine Research
Tracey Day,
Infectious Disease Research Institute, USA
Clinical Development of ID93+GLA-SE as a Prophylactic or Therapeutic Vaccine for Tuberculosis
Clinical Development of ID93+GLA-SE as a Prophylactic or Therapeutic Vaccine for Tuberculosis
Stephen C. De Rosa,
University of Washington, Fred Hutchinson Cancer Research Center, USA
BCG Revaccination Significantly Boosts Circulating, Polyfunctional, Mtb-Specific CD4 T Cell Effector Responses in Young Adults with Latent TB Living in South India
BCG Revaccination Significantly Boosts Circulating, Polyfunctional, Mtb-Specific CD4 T Cell Effector Responses in Young Adults with Latent TB Living in South India
Karin Dijkman,
Biomedical Primate Research Centre, Netherlands
Local IL17A after Mucosal BCG Vaccination Associates with Protection from Infection and Disease in a Novel, Repeated Ultra-Low Dose TB Challenge Model in Rhesus Macaques
Local IL17A after Mucosal BCG Vaccination Associates with Protection from Infection and Disease in a Novel, Repeated Ultra-Low Dose TB Challenge Model in Rhesus Macaques
Ved Prakash Dwivedi,
International Center for Genetic Engineering and Biotechnology, India
Mimicking Mycobacterium tuberculosis for the Immunization in the Lung thereby Generating Effective Vaccine in the Local Milieu
Mimicking Mycobacterium tuberculosis for the Immunization in the Lung thereby Generating Effective Vaccine in the Local Milieu
Sasha E. Larsen,
Universty of Washington, USA
Therapeutic Immunizations Induce Control of Bacterial Burden and Increase Survival in a Preclinical Mouse Model of Mycobacterium tuberculosis
Therapeutic Immunizations Induce Control of Bacterial Burden and Increase Survival in a Preclinical Mouse Model of Mycobacterium tuberculosis
Elisa Nemes,
University of Cape Town, South Africa
Prevention of Infection with Mycobacterium tuberculosis by H4:IC31® Vaccination or BCG Revaccination in Adolescents
Prevention of Infection with Mycobacterium tuberculosis by H4:IC31® Vaccination or BCG Revaccination in Adolescents
17:00—19:00
New and Old Players in Mucosal Immunity and their Role in HIV/SIV Infection
*
Barbara L. Shacklett,
University of California, Davis, USA
*
Karl Salzwedel,
NIAID, National Institutes of Health, USA
Johan K. Sandberg,
Karolinska Institute, Sweden
Role of MAIT Cells in Immune Defense and HIV Immunopathogenesis
Role of MAIT Cells in Immune Defense and HIV Immunopathogenesis
Petronela Ancuta,
Centre de Recherche de l'Universite de Montreal, Canada
HIV Persistence in Th17 Cells: Finding New Ways to Cure
HIV Persistence in Th17 Cells: Finding New Ways to Cure
Jason M. Brenchley,
NIAID, National Institutes of Health, USA
Mechanisms Underlying Loss of ILCs in Progressive SIV Infection
Mechanisms Underlying Loss of ILCs in Progressive SIV Infection
Dominic Paquin Proulx,
US Military HIV Research Program, USA
Short Talk: Permanent Loss of Regulatory Colonic CD4+ iNKT Cells in Early Acute HIV-1 Infection
Short Talk: Permanent Loss of Regulatory Colonic CD4+ iNKT Cells in Early Acute HIV-1 Infection
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
17:00—19:00
Mycobacterium Tuberculosis and Host Evasion
*
Sarah M. Fortune,
Harvard TH Chan School of Public Health, USA
*
Joel D. Ernst,
University of California, San Francisco, USA
JoAnne L. Flynn,
University of Pittsburgh School of Medicine, USA
Granuloma Dynamics in Tuberculosis
Granuloma Dynamics in Tuberculosis
Robert A. Seder,
NIAID, National Institutes of Health, USA
A Novel Approach to BCG Vaccination in the NHP Model
A Novel Approach to BCG Vaccination in the NHP Model
Jennifer Philips,
Washington University School of Medicine, USA
Hijacking the Host – Molecular Interactions between Host and Pathogen
Hijacking the Host – Molecular Interactions between Host and Pathogen
Samuel M. Behar,
University of Massachusetts Medical School, USA
Short Talk: Decoy Antigens Elicit Immunodominant T Cell Responses that Fail to Recognize Infected Macrophages
Short Talk: Decoy Antigens Elicit Immunodominant T Cell Responses that Fail to Recognize Infected Macrophages
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Innate Responses in HIV and SIV Infection: The Good, the Bad and the Splendid
*
R. Keith Reeves,
Harvard Medical School, USA
*
Anthony L. Cunningham,
Westmead Institute for Medical Research, Australia
Marcus Altfeld,
Heinrich-Pette-Institute, Germany
Innate Immune Responses in HIV-1: Mediators of Viral Control and Immune Activation
Innate Immune Responses in HIV-1: Mediators of Viral Control and Immune Activation
Michaela Müller-Trutwin,
Institut Pasteur, France
Innate Immune Responses in Non-Pathogenic SIV Infection
Innate Immune Responses in Non-Pathogenic SIV Infection
Coffee Break
Teunis B.H. Geijtenbeek,
University of Amsterdam, Netherlands
Innate Responses by Dendritic Cells in HIV Infection – A Role in Pathogenesis
Innate Responses by Dendritic Cells in HIV Infection – A Role in Pathogenesis
Tram N.Q. Pham,
Institut de Recherches Cliniques de Montreal, Canada
Short Talk: Flt3L Treatment Reduces HIV Infection and Replication in Humanized Mice via a Plasmacytoid Dendritic Cell-Dependent Process
Short Talk: Flt3L Treatment Reduces HIV Infection and Replication in Humanized Mice via a Plasmacytoid Dendritic Cell-Dependent Process
Henrik N. Kloverpris,
University of KwaZulu-Natal, South Africa
Short Talk: HIV-Infected Children Have Life-Long Depletion of all Circulating Innate Lymphoid Cells (ILCs) but Respond to Infection through Tissue-Resident ILCs
Short Talk: HIV-Infected Children Have Life-Long Depletion of all Circulating Innate Lymphoid Cells (ILCs) but Respond to Infection through Tissue-Resident ILCs
Daniel Claiborne,
Ragon Institute of MGH, MIT, and Harvard, USA
Short Talk: Integral Role of Monocytes in Immune Activation during HIV-1 Infection
Short Talk: Integral Role of Monocytes in Immune Activation during HIV-1 Infection
Ivona Pandrea,
University of Pittsburgh, USA
Short Talk: Neutrophil Extracellular Trap (NET) Production in SIV-Infected Nonhuman Primates
Short Talk: Neutrophil Extracellular Trap (NET) Production in SIV-Infected Nonhuman Primates
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
08:00—11:15
Drug Tolerance and Resistance
*
Sabine Ehrt,
Weill Cornell Medical College, USA
*
Christopher M. Sassetti,
University of Massachusetts Medical School, USA
Eric J. Rubin,
Harvard T.H. Chan School of Public Health, USA
I Guess You're Just What I Needed – What Does it Mean to Be Essential?
I Guess You're Just What I Needed – What Does it Mean to Be Essential?
Bree B. Aldridge,
Tufts University, USA
Efficient Measurement and Analysis of High-Order Drug Interactions
Efficient Measurement and Analysis of High-Order Drug Interactions
Coffee Break
Mark Ragheb,
University of Washington, USA
Short Talk: Mfd Promotes Rapid Evolution of Antibiotic Resistance
Short Talk: Mfd Promotes Rapid Evolution of Antibiotic Resistance
Sarah M. Fortune,
Harvard TH Chan School of Public Health, USA
Multi-Drug-Tolerant Mutants Identified through a Population GWAS
Multi-Drug-Tolerant Mutants Identified through a Population GWAS
Bryan J. Berube,
Infectious Disease Research Institute, USA
Short Talk: Dual Targeting of the M. tuberculosis Electron-Transport Chain Enhances Bacterial Killing and Limits Spontaneous Mutant Formation
Short Talk: Dual Targeting of the M. tuberculosis Electron-Transport Chain Enhances Bacterial Killing and Limits Spontaneous Mutant Formation
14:30—16:30
Workshop 2: HIV, TB and Other Co-Infections (Joint)
*
Donald L. Sodora,
Center for Infectious Disease Research, USA
*
Shelby O'Connor,
University of Wisconson-Madison, USA
Allison Nicole Bucsan,
Tulane National Primate Research Center, USA
Mtb/SIV Co-Infection Induces Differential T Cell Responses in Rhesus Macaques
Mtb/SIV Co-Infection Induces Differential T Cell Responses in Rhesus Macaques
Anna Kathleen Coussens,
Walter and Eliza Hall Institute, Australia
GBPs in TB-HIV, A Double-Edge Sword in Prevention and Progression
GBPs in TB-HIV, A Double-Edge Sword in Prevention and Progression
Rabiah Fardoos,
Africa Health Research Institute, South Africa
Profiling of HIV and CMV-Specific CD8+ T-Cells Isolated from HIV-Infected Human Lymphoid Tissue Display a Distinct Phenotype Compartmentalization
Profiling of HIV and CMV-Specific CD8+ T-Cells Isolated from HIV-Infected Human Lymphoid Tissue Display a Distinct Phenotype Compartmentalization
Collin Richard Diedrich,
University of Pittsburgh, USA
SIVmac251 and Neutralizing CD4 T Cell Antibodies Induce Reactivation of Latent Tuberculosis Infection by Distinct Mechanisms
SIVmac251 and Neutralizing CD4 T Cell Antibodies Induce Reactivation of Latent Tuberculosis Infection by Distinct Mechanisms
Amy Kathryn Dickey,
Massachusetts General Hospital, Ragon Institute, USA
Slam Family Receptors May Act as Inhibitory Receptors in the Airways of HIV-Infected Individuals
Slam Family Receptors May Act as Inhibitory Receptors in the Airways of HIV-Infected Individuals
Annapurna Vyakarnam,
King's College London, UK
HIV Alters the Mtb-Specific Th17 Response in Latent TB
HIV Alters the Mtb-Specific Th17 Response in Latent TB
Joshua T. Mattila,
University of Pittsburgh, USA
Type 3 Interferons Are Expressed in Tuberculous Granulomas and May Influence Signaling in Epithelioid Macrophages
Type 3 Interferons Are Expressed in Tuberculous Granulomas and May Influence Signaling in Epithelioid Macrophages
Fatoumatta Darboe,
Medical Research Council, The Gambia Unit, Gambia
A Transcriptomic Risk Signature Predicts Subclinical TB in HIV-Infected Persons on Highly Active Antiretroviral Therapy
A Transcriptomic Risk Signature Predicts Subclinical TB in HIV-Infected Persons on Highly Active Antiretroviral Therapy
17:00—19:00
New Insights in Pathogenesis: Tissue Is the Issue
*
Thomas J. Hope,
Northwestern University, USA
*
Marianne E. Jansson,
Lund University, Sweden
Michael R. Betts,
University of Pennsylvania, USA
Lymphocyte Trafficking in HIV Infection
Lymphocyte Trafficking in HIV Infection
Shelli Farhadian,
Yale School of Medicine, USA
Short Talk: Single-Cell RNA Sequencing to Characterize CSF during Virologically Suppressed HIV
Short Talk: Single-Cell RNA Sequencing to Characterize CSF during Virologically Suppressed HIV
Abigail E. Schiff,
Harvard University, USA
Short Talk: Investigation of Alveolar Macrophage Phagocytosis of HIV-Infected T Cells as a Mechanism of HIV-1 Entry into Macrophages
Short Talk: Investigation of Alveolar Macrophage Phagocytosis of HIV-Infected T Cells as a Mechanism of HIV-1 Entry into Macrophages
Johanne Hovgaard Egedal,
Aarhus University, Denmark
Short Talk: Hyaluronic Acid on Mucosal Fibroblasts Limits their Ability to Enhance HIV Infection of CD4+ T Cells
Short Talk: Hyaluronic Acid on Mucosal Fibroblasts Limits their Ability to Enhance HIV Infection of CD4+ T Cells
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
17:00—19:00
Immune-Pathogen Interaction: Containment or Progression?
*
Tom H. M. Ottenhoff,
Leiden University Medical Center, Netherlands
*
Clifton E. Barry III,
NIAID, National Institutes of Health, USA
Bryan D. Bryson,
Massachusetts Institute of Technology, USA
Enhancing Control of Mycobacterium tuberculosis Infection with Single-cell Resolution
Enhancing Control of Mycobacterium tuberculosis Infection with Single-cell Resolution
Christina L. Stallings,
Washington University School of Medicine, USA
Innate Immune Determinants of TB Progression
Innate Immune Determinants of TB Progression
David M. Lewinsohn,
Oregon Health & Science University, USA
MAIT Cell Responses to the TB Metabolome and Implications for Vaccine Development
MAIT Cell Responses to the TB Metabolome and Implications for Vaccine Development
Daisy Xiaoxi Ji,
University of California, Berkeley, USA
Short Talk: A Mechanism for Interferon-Driven Susceptibility to M. tuberculosis
Short Talk: A Mechanism for Interferon-Driven Susceptibility to M. tuberculosis
08:00—11:15
HIV and TB: Double Trouble (Joint)
*
Michaela Müller-Trutwin,
Institut Pasteur, France
*
Richard E. Chaisson,
Johns Hopkins University, USA
Graeme Meintjes,
University of Cape Town, South Africa
High Early Mortality in Patients Diagnosed with HIV-Associated TB in Hospital
High Early Mortality in Patients Diagnosed with HIV-Associated TB in Hospital
Gregory Bisson,
University of Pennsylvania, USA
To Have and Have Not: Immune Restoration and Lung Injury in HIV/TB
To Have and Have Not: Immune Restoration and Lung Injury in HIV/TB
Coffee Break
Irini Sereti,
NIAID, National Institutes of Health, USA
Role of Co-Infections in HIV Inflammation and Persistence
Role of Co-Infections in HIV Inflammation and Persistence
Henry Charles Mwandumba,
Liverpool School of Tropical Medicine, UK
HIV and TB Co-Infection: A View from the Lungs
HIV and TB Co-Infection: A View from the Lungs
Daniel Kalman,
Emory University, USA
Short Talk: The Imatinib-TB Clinical Trial
Short Talk: The Imatinib-TB Clinical Trial
Mark Andrew Rodgers,
University of Pittsburgh, USA
Short Talk: Pre-Existing SIV Infection Increases Susceptibility of Mauritian Cynomolgus Macaques to M. tuberculosis
Short Talk: Pre-Existing SIV Infection Increases Susceptibility of Mauritian Cynomolgus Macaques to M. tuberculosis
11:15—12:15
Grantsmanship Workshop presented by NIAID (Joint)
NIAID Workshop Objectives:
Come find out what happens to your applications after you submit it to the NIH. NIAID staff will provide attendees with an overview of NIH peer-review, and provide some grantsmanship tips. NIAID Program Officers and Scientific Review Officers will explain their role in shepherding your grants/proposals through the process. Staff will also provide attendees with resources that will alert them to NIAID funding opportunities and discuss specific opportunities targeted to research in mycobacterial diseases. Finally, time permitting staff will discuss various career opportunities within the NIH.
*
Alison Kraigsley,
NIAID, National Institutes of Health, USA
*
Karen Lacourciere,
NIAID, National Institutes of Health, USA
*
Susana Mendez,
NIAID, National Institutes of Health, USA
*
Vasundhara Varthakavi,
NIDA, National Institutes of Health, USA
*
Roberta Binder,
NIAID, National Institutes of Health, USA
*
Chelsea Boyd,
NIAID, National Institutes of Health, USA
14:30—16:30
Workshop 3: Persistence, Latency and Eradication
*
Remi Fromentin,
Le Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Canada
*
Alberto Bosque,
George Washington University, USA
Christina Gavegnano,
Emory University, USA
Baricitinib Reverses HIV-Associated Neurocognitive Disorders and Reservoir Seeding in a SCID Mouse Model
Baricitinib Reverses HIV-Associated Neurocognitive Disorders and Reservoir Seeding in a SCID Mouse Model
Patrick Budylowski,
University or Toronto, Canada
Discovering Novel Surface Biomarkers on Latent HIV-Infected CD4 T Cells using VLR Antibodies
Discovering Novel Surface Biomarkers on Latent HIV-Infected CD4 T Cells using VLR Antibodies
Namita Satija,
Icahn School of Medicine at Mount Sinai, USA
A Genetically Encoded Switch to Monitor HIV Latent Cells in Humanized Mice
A Genetically Encoded Switch to Monitor HIV Latent Cells in Humanized Mice
Mykola Pinkevych,
University of New South Wales, Australia
Using a Barcoded Virus to Assess Replication Competent SIV Reservoir Size
Using a Barcoded Virus to Assess Replication Competent SIV Reservoir Size
Sara Cristinelli,
University of Lausanne, Switzerland
Single-Cell RNA-Seq Reveals Transcriptional Heterogeneity in Latent and Reactivated HIV-Infected Cells
Single-Cell RNA-Seq Reveals Transcriptional Heterogeneity in Latent and Reactivated HIV-Infected Cells
Gregory Q. Del Prete,
Frederick National Laboratory for Cancer Research, USA
CD4 Depletion in SIV-Infected Macaques on Early ART Has No Impact on Viral Rebound
CD4 Depletion in SIV-Infected Macaques on Early ART Has No Impact on Viral Rebound
Maria-Louise Røn Kobberø,
Aarhus University Hospital, Denmark
Immunological Effects of Toll-Like Receptor 9 Agonist Treatment in Lymph Nodes of HIV-1+ Adults on ART
Immunological Effects of Toll-Like Receptor 9 Agonist Treatment in Lymph Nodes of HIV-1+ Adults on ART
Mirko Paiardini,
Emory University, YNPRC, USA
IL-10 Signaling Contributes to Viral Persistence in ART-Treated, SIV-Infected Rhesus Macaques
IL-10 Signaling Contributes to Viral Persistence in ART-Treated, SIV-Infected Rhesus Macaques
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
14:30—16:30
Workshop 3: MTB Growth and Death
*
Eric J. Rubin,
Harvard T.H. Chan School of Public Health, USA
*
Bavesh Davandra Kana,
University of the Witwatersrand, South Africa
Piyali S. Basu,
University of Surrey, UK
Nitrogen Metabolism in Mycobacterium tuberculosis: A Systems-Based Approach
Nitrogen Metabolism in Mycobacterium tuberculosis: A Systems-Based Approach
Viktoria Betin,
Harvard University, USA
Determining How Mycobacterium tuberculosis Transcriptional Regulators Influence Intracellular Replication
Determining How Mycobacterium tuberculosis Transcriptional Regulators Influence Intracellular Replication
Allison F. Carey,
Harvard School of Public Health, USA
TnSeq of M. tuberculosis Clinical Isolates Reveals Strain-Specific Antibiotic Liabilities
TnSeq of M. tuberculosis Clinical Isolates Reveals Strain-Specific Antibiotic Liabilities
Marcus A. Horwitz,
University of California, Los Angeles, USA
Identification by Parabolic Response Surface Methodology of a Universal TB Drug Treatment Regimen that, Compared with the Standard Regimen, Reduces the Time to Achieve Relapse-Free Cure in Mice from 20 Weeks to Only 4 Weeks
Identification by Parabolic Response Surface Methodology of a Universal TB Drug Treatment Regimen that, Compared with the Standard Regimen, Reduces the Time to Achieve Relapse-Free Cure in Mice from 20 Weeks to Only 4 Weeks
Johana Hernandez,
University of Surrey, UK
Investigating Candidate Genes Affecting Persistence (drug tolerance) of Mycobacterium tuberculosis Obtained by Tn-Seq Analysis
Investigating Candidate Genes Affecting Persistence (drug tolerance) of Mycobacterium tuberculosis Obtained by Tn-Seq Analysis
Christopher R. Covey,
University of Colorado, USA
Myocbactin Inhibits Clofazimine Killing of Mycobacteria
Myocbactin Inhibits Clofazimine Killing of Mycobacteria
John T. Williams,
Michigan State University, USA
Novel Inhibitors that Kill Mycobacterium tuberculosis by Targeting MmpL3
Novel Inhibitors that Kill Mycobacterium tuberculosis by Targeting MmpL3
Hua Wang,
Francis Crick Institute, UK
The Discovery of a Multi-Functional acyl-CoA Lyase Shared by Three Metabolic Pathways in Mycobacterium tuberculosis
The Discovery of a Multi-Functional acyl-CoA Lyase Shared by Three Metabolic Pathways in Mycobacterium tuberculosis
17:00—19:00
HIV and Co-infections: Dangerous Liaison
*
Peter W. Hunt,
University of California, San Francisco, USA
*
Neeltje A. Kootstra,
Amsterdam UMC, Netherlands
Stephen R. Morris,
Louis Stokes Cleveland VA Medical Center, USA
Short Talk: IL-15 Drives the Generation and Survival of Senescent CD8 T Cells in HIV/CMV Co-Infection
Short Talk: IL-15 Drives the Generation and Survival of Senescent CD8 T Cells in HIV/CMV Co-Infection
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
17:00—19:00
The Cellular, Anatomical and Pathological Niches of TB Infection and Disease
*
Graeme Meintjes,
University of Cape Town, South Africa
*
David M. Lewinsohn,
Oregon Health & Science University, USA
Clifton E. Barry III,
NIAID, National Institutes of Health, USA
Imaging TB
Imaging TB
Sabine Ehrt,
Weill Cornell Medical College, USA
Resist, Persist and Divide
Resist, Persist and Divide
Veronique Anne Dartois,
Hackensack Meridian Health, USA
Lesion-Centric Pharmacology to Design New Drug Regimens for Tuberculosis
Lesion-Centric Pharmacology to Design New Drug Regimens for Tuberculosis
Valerie A.C.M. Koeken,
Radboud University Medical Center, Netherlands
Short Talk: Survival of Tuberculous Meningitis Is Linked to Cerebrospinal Fluid Vascular Endothelial Growth Factor (VEGF); a Systems Approach
Short Talk: Survival of Tuberculous Meningitis Is Linked to Cerebrospinal Fluid Vascular Endothelial Growth Factor (VEGF); a Systems Approach
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
HIV Persistence and Latency: The Enemy Within
*
Mark Brockman,
Simon Fraser University, Canada
*
Camille M. Lange,
National Cancer Institute, USA
Coffee Break
James I. Mullins,
University of Washington, USA
HIV Integration Sites and Selection for Infected Cell Survival in Persisting Reservoirs
HIV Integration Sites and Selection for Infected Cell Survival in Persisting Reservoirs
Kelsie Brooks,
Emory University, USA
Short Talk: Proviral Sequences of the Reservoir Demonstrate Archiving of Transmitted/Founder Virus-Like Variants
Short Talk: Proviral Sequences of the Reservoir Demonstrate Archiving of Transmitted/Founder Virus-Like Variants
Timothée Bruel,
Institut Pasteur, France
Short Talk: Characterization of Circulating CD32a+ CD4 T Cells and Identification of Potent ADCC-Mediating CD32 Antibodies
Short Talk: Characterization of Circulating CD32a+ CD4 T Cells and Identification of Potent ADCC-Mediating CD32 Antibodies
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
08:00—11:15
Bacterial Adaptation
*
Luiz Pedro Carvalho,
Francis Crick Institute, UK
*
Sabine Ehrt,
Weill Cornell Medical College, USA
David Alland,
Rutgers University, New Jersey Medical School, USA
Genetic Diversity of Mycobacterium tuberculosis as a Driver of Drug Resistance and Relapse in Human TB
Genetic Diversity of Mycobacterium tuberculosis as a Driver of Drug Resistance and Relapse in Human TB
Stefan Niemann,
Research Center Borstel, Germany
Recent Evolution and Transmission of MDR M. tuberculosis Strains
Recent Evolution and Transmission of MDR M. tuberculosis Strains
Coffee Break
Sarah Bwabye Namugenyi,
University of Minnesota, USA
Short Talk: Identification of Mycobacterium tuberculosis Immune Evasion Mechanisms using Tn-seq
Short Talk: Identification of Mycobacterium tuberculosis Immune Evasion Mechanisms using Tn-seq
Babak Javid,
Tsinghua University School of Medicine, China
Targeting Mycobacterial Adaptive Mistranslation in Vitro and in Vivo
Targeting Mycobacterial Adaptive Mistranslation in Vitro and in Vivo
Eduardo Pinheiro Amaral,
NIAID, National Institutes of Health, USA
Short Talk: Ferroptosis, an Iron-Dependent Cell Death Modality, Is a Major Mechanism of Regulated Necrosis in Mycobacterium tuberculosis Infection
Short Talk: Ferroptosis, an Iron-Dependent Cell Death Modality, Is a Major Mechanism of Regulated Necrosis in Mycobacterium tuberculosis Infection
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
14:30—16:30
Workshop 4: The Immune Response to TB
*
Bryan D. Bryson,
Massachusetts Institute of Technology, USA
*
Thomas J. Scriba,
University of Cape Town, South Africa
Jayne S. Sutherland,
Medical Research Council, Gambia
Analysis of Early Protective Immunity to Mycobacterium tuberculosis Infection
Analysis of Early Protective Immunity to Mycobacterium tuberculosis Infection
Amanda Lee Ardain,
Africa Health Research Institute, South Africa
Innate Lymphoid Cells Mediate Early Protective Immunity against Mycobacterium tuberculosis
Innate Lymphoid Cells Mediate Early Protective Immunity against Mycobacterium tuberculosis
Eusondia Arnett,
Texas Biomedical Research Institute, USA
Use of a Tissue Culture Model to Characterize M. tuberculosis HIV Co-Infected Human Granuloma Development
Use of a Tissue Culture Model to Characterize M. tuberculosis HIV Co-Infected Human Granuloma Development
Julie Boucau,
Ragon Institute of MGH, MIT and Harvard, USA
Mycobacterium tuberculosis Antigens Are Differentially Degraded into Epitopes by Human Monocyte-Derived Dendritic Cells and Macrophages
Mycobacterium tuberculosis Antigens Are Differentially Degraded into Epitopes by Human Monocyte-Derived Dendritic Cells and Macrophages
Natasha M. Bourgeois,
University of Washington School of Medicine, USA
Host-Directed Macrophage Therapy with Kinase Inhibitors Limit Mycobacterium tuberculosis Replication and Modulate Cytokine Signaling
Host-Directed Macrophage Therapy with Kinase Inhibitors Limit Mycobacterium tuberculosis Replication and Modulate Cytokine Signaling
Alissa C. Rothchild,
Seattle Children's Research Institute, USA
In vivo Response of Alveolar Macrophages to Mycobacterium tuberculosis
In vivo Response of Alveolar Macrophages to Mycobacterium tuberculosis
Munyaradzi Nyasha Musvosvi,
University of Cape Town, South Africa
T Cell Biomarkers for Diagnosis of Tuberculosis: Candidate Evaluation by a Simple Whole Blood Assay for Clinical Translation
T Cell Biomarkers for Diagnosis of Tuberculosis: Candidate Evaluation by a Simple Whole Blood Assay for Clinical Translation
Michael D. Stutz,
, Australia
Harnessing the Therapeutic Potential of Endogenous TNF for the Treatment of Tuberculosis
Harnessing the Therapeutic Potential of Endogenous TNF for the Treatment of Tuberculosis
17:00—18:45
Strategies for HIV Remission and Cure
*
Jana Blazkova,
NIAID, National Institutes of Health, USA
*
Michael M. Lederman,
Case Western Reserve University, USA
Asier Sáez-Cirión,
Institut Pasteur, France
Cell Metabolism and HIV Control
Cell Metabolism and HIV Control
Romas Geleziunas,
Gilead Sciences, Inc., USA
TLR7 Agonists for HIV
TLR7 Agonists for HIV
Paula M. Cannon,
University of Southern California, Keck School of Medicine, USA
Genetic Strategies for HIV Cure
Genetic Strategies for HIV Cure
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
17:00—18:45
New Frontiers in TB Diagnostics and Treatment
*
David Alland,
Rutgers University, New Jersey Medical School, USA
Bavesh Davandra Kana,
University of the Witwatersrand, South Africa
Differentially Culturable Tubercle Bacteria: Implications for Diagnosis and Measuring Treatment Efficacy
Differentially Culturable Tubercle Bacteria: Implications for Diagnosis and Measuring Treatment Efficacy
Nader Fotouhi,
TB Alliance, USA
TB Alliance Drugs in Development
TB Alliance Drugs in Development
Jane Hill,
Dartmouth College, USA
Exhaled Breath: A Diagnostic Fluid that also Generates Insight into Pathogenesis
Exhaled Breath: A Diagnostic Fluid that also Generates Insight into Pathogenesis
Following Session is for Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
|
|
We gratefully acknowledge additional support for this conference from:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
